WR
William Redmond
Earle A. Chiles Research Institute, Earle A Chiles Research Institute, Scripps Research Institute
0000-0002-2572-1731
Employment
-
Earle A. Chiles Research Institute Full Member2021 - Present
-
Earle A Chiles Research Institute Director, Immune Monitoring Laboratory2016 - Present
-
Earle A. Chiles Research Institute Associate Member2015 - Present
-
Earle A Chiles Research Institute Assistant Member2009 - 2015
Education
-
Scripps Research Institute PhD1999 - 2004
Projects & Funding
Projects & funding information is unavailable.
Publications (65)
- Bacterial colonization of tumors drives immune activation and checkpoint blockade efficacy Save
- Peri-lymphatic cytokines (IRX-2) as immunologic induction preceding neoadjuvant chemo-immunotherapy in triple-negative breast cancer Save
- Ovarian tumor cells gain competitive advantage by actively reducing the cellular fitness of microenvironment cells Save
- SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy Save
- INBRX-106: a hexavalent OX40 agonist that drives superior antitumor responses via optimized receptor clustering Save
- The response to anti–PD-1 and anti–LAG-3 checkpoint blockade is associated with regulatory T cell reprogramming Save
- Current landscape and future prospects of interleukin-2 receptor (IL-2R) agonists in cancer immunotherapy Save
- Challenges and opportunities in the development of combination immunotherapy with OX40 agonists Save
- A phase Ib trial of pembrolizumab plus paclitaxel or flat-dose capecitabine in 1st/2nd line metastatic triple-negative breast cancer Save
- Data from Enhancing the Generation of Eomeshi CD8+ T Cells Augments the Efficacy of OX40- and CTLA-4–Targeted Immunotherapy Save